Oxford University’s experimental coronavirus vaccine is the first to enter the final stages of human testing. The vaccine, called ChAdOx1 nCoV-19, is being made with partner AstraZeneca.
This experimental coronavirus vaccine has been in human testing since April. Vaccine testing is broken up into phases with each phase progressively introducing more participants to the vaccine.
The initial vaccine testing consisted of over 1,000 healthy British volunteers. The volunteers were aged 18-55. Phase 2 was conducted last month with about 10,000 participants. Phase 3 has already begun. A South African received the first dose of this stage. About 2,000 South Africans will be tested on. 5,000 Brazilians and 4,000 British people will also be tested on. 10,000 more participants are planned, An additional 30,000 volunteers from the United States are expected to undergo testing as well.
A study from the Britain Pirbright Institute in pigs has shown that 2 doses produces a greater antibody response than 1.
Organizational coronavirus treatment funding and distribution
AstraZeneca has struck up multiple deals with many companies. They are supplying up to 400 million doses to European Union countries. Another deal with the Vaccine Alliance outlines up to 700 million doses to the U.S and other countries in the Americas. The Serum Institute of India has invested around $100 million and in return will receive 1 billion doses.
The American Government has invested $1 billion. They are hoping for 300 million doses by the end of the year.
The scientific journal PLOS One, did a study on vaccine development. According to the study, the average vaccine takes 10.71 years to be released on the market. Furthermore, only 6% of vaccines that start actually finish the process. If Oxford and AstraZeneca can pull it off, then it would be a record-breaking time for a vaccine to be put on the market.
The race for companies to be first with a vaccine intensifies. Studies are continuing and many breakthroughs are happening. More information will be publicly released as these studies continue.